Patents Assigned to ALTIF LABORATORIES INC.
  • Patent number: 9315790
    Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 19, 2016
    Assignees: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, ALTIF LABORATORIES INC.
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Ikuo Kawashima, Seiichi Aikawa, Fumiko Aikawa
  • Publication number: 20140044699
    Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: September 13, 2013
    Publication date: February 13, 2014
    Applicants: ALTIF LABORATORIES INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Hitoshi SAKURABA, Youichi TAJIMA, Ikuo KAWASHIMA, Seiichi AIKAWA, Fumiko AIKAWA
  • Publication number: 20100291059
    Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: May 19, 2008
    Publication date: November 18, 2010
    Applicants: ALTIF LABORATORIES INC.
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Ikuo Kawashima, Seiichi Aikawa, Fumiko Aikawa